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Many physicians have experience using generic
drugs in their practice. Generics tend to be
small molecules with a relatively simple structure
and are identical to licensed reference products.
Generic compounds typically are synthesized
using organic medicinal chemistry. Variations in the
manufacturing process are unlikely to have a major
impact on the final product, an outcome that is
verified through analytical characterization of the
generic.
A biosimilar biotherapeutic is a protein.
Biosimilar products are quite different from generic
drugs. A biosimilar has similar quality, safety, and
efficacy to a licensed reference product, but it is
not necessarily identical to the reference product
with regard to these properties.[1] In contrast to
generic drugs, biosimilars tend to have complex
structures and may differ from the reference
product in their primary amino acid sequence
and other features such as glycosylation and
PEGylation that alter their tertiary structure (i.e.,
protein folding) as well as their immunogenicity.[2]
These differences arise from the manufacturing
process, which tends to be much more complex
than that of generic drugs. Typically, a biosimilar
protein is synthesized by transfecting a target cell
with a DNA sequence that encodes the desired
product. Often, transfected mammalian cells are
required to produce complex proteins, but these
cells typically have lower yields than bacterial
hosts. The initial product must be purified to
remove undesired proteins. As one might expect,
the use of different expression systems can be
associated with different post-translational protein
modifications.
Changes in the manufacturing process are thus
critical (and essential to avoid patent infringement
on proprietary biomanufacturing processes), as
they may alter protein structure and function.
Analytical characterization of these compounds
is not straightforward and, in any case, is not
expected to reveal structure and properties
identical to the reference product if different
vectors, expression systems, purification steps, and
excipients are used in the manufacturing process.
Analysis of the immunogenicity of a biosimilar,
for example, is a critical aspect of evaluating the
therapeutic modality, whereas a generic drug is
expected to be identical to the reference product
in this regard. The development process and
quality control for biosimilars are challenging,[3, 4]
which helps to explain why the manufacturing
costs for biosimilars and generic drugs are quite
different, averaging $100–200 million/molecule for
the former and $3–5 million/molecule for the latter.
Accordingly, the price reduction for biosimilars
versus generic drugs is less and might be on the
order of 20–30%.
Clinical trials of biosimilars must demonstrate
safety and efficacy comparable to the
reference product regarding pharmacokinetic,
pharmacodynamic, and immunogenic properties.
If phase 3 studies are successful and a biosimilar
is approved for one indication, it is approved for all
other indications for which the reference product
is approved, provided there is adequate scientific
justification.[5, 6] In general, there is an expectation
that a patient can switch from a biosimilar to the
reference product and vice versa with no lapse in
therapeutic efficacy or increased risk. Switching
studies demonstrating interchangeability of
biosimilars and reference products have not been
required for marketing approval by the European
Medicine Agency,[6] whereas they are required by
the US Food and Drug Administration (US FDA)
(https://www.fda.gov/media/124907/download). In
order to assist physicians in identifying biosimilars
versus the reference product and avoid inadvertent
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product substitution, the US FDA determined
that each biosimilar’s name should comprise a
core name hyphenated with a four-letter suffix
representing the developer.[7]
Studies such as the one reported by Lashay
and coworkers in this issue of the Journal of
Ophthalmic and Vision Research constitute an
essential step toward adopting use of Stivant,
a biosimilar to bevacizumab, for non-approved
ophthalmic indications.[8] This work has been
executed expertly and provides reassurance that
Stivant may well be an appropriate substitute for
intravitreal bevacizumab, which is more expensive.
The authors qualify their results with great care,
but it may be worth emphasizing a few points.
First, the rabbit retina is merangiotic and has
no fovea. Apart from the inability to identify
drug effects on foveal function, these and other
features of the rabbit eye may lead to differences
in the intraocular and systemic pharmacokinetic
profile of the drug associated with intravitreal
injection in human patients. Also, although the
dose administered was much higher than that
anticipated for human subjects, a dose response
curve was not undertaken. While we may conclude
that a dose of 1.25 mg in a normal size human
eye is likely to be safe, we do not know the upper
bound of a safe dose based on the data provided.
Naturally, these animals had healthy eyes. We do
not know whether the safety profile observed in
this work will be the same in eyes with damaged
retina, retinal pigment epithelium, and/or choroid,
as will be encountered in patients with diabetic
retinopathy, retinal vein occlusion, and age-related
macular degeneration. Of course, these same
limitations apply to studies using bevacizumab in
rabbits, but biosimilars can differ in subtle ways
from the licensed product theymimic. Nonetheless,
the data provided by Lashay and coworkers are
positive and justify additional studies that will
enable Stivant to be deployed for clinical use in
patients with retinal vascular diseases. Ultimately,
efforts such as thesewill enable us to provide sight-
saving therapy to many more patients through the
cost savings realized by the use of biosimilars. I
commend the authors for this excellent work and
look forward to additional progress in this area. We
and our patients will benefit enormously from their
efforts.
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